# S1 STROBE checklist

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract Abstract, Methodology/Findings, §1  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found |
| **Introduction** | 2 | Explain the scientific background and rationale for the investigation being reported § 1 to 4 |
| **Objectives** | 3 | State specific objectives, including any prespecified hypotheses § 5 |
| **Methods** | 4 | Present key elements of study design early in the paper  
Study area, design and population: § 1 |
| **Setting** | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  
Study area, design and population: § 2 |
| **Participants** | 6 | (a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
*Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  
*Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants  
Study area, design and population: §2, 3, 4  
(b) **Cohort study**—For matched studies, give matching criteria and number of exposed and unexposed  
*Case-control study*—For matched studies, give matching criteria and the number of controls per case |
| **Variables** | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  
Clinical assessment  
Assessment of parasitological infection, § 2, 3 |
| **Data sources/measurement** | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  
Clinical assessment  
Assessment of parasitological infection, § 1 |
| **Bias** | 9 | Describe any efforts to address potential sources of bias  
Assessment of parasitological infection, § 2, 3 |
| **Study size** | 10 | Explain how the study size was arrived at  
Study area, design and population: §2, 3, 4  
Assessment of parasitological infection, § 3 |
### Quantitative variables

11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why.

- Data management and statistical analysis, §1, 4, 5
- Assessment of parasitological infection, §2

### Statistical methods

12

(a) Describe all statistical methods, including those used to control for confounding

- Data management and statistical analysis, §2, 3, 5

(b) Describe any methods used to examine subgroups and interactions

- Data management and statistical analysis, §5

(c) Explain how missing data were addressed

- Assessment of parasitological infection, §3

(d) **Cohort study**—If applicable, explain how loss to follow-up was addressed

(e) **Case-control study**—If applicable, explain how matching of cases and controls was addressed

(f) **Cross-sectional study**—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

### Results

#### Participants

13*

(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed

- Study population, §1, 2, 3, 4

(b) Give reasons for non-participation at each stage

- Study population, §1, 2, 3, 4

(c) Consider use of a flow diagram

- Fig 1

#### Descriptive data

14*

(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders

- Table 1, SI Table

(b) Indicate number of participants with missing data for each variable of interest

- Study population, §1, 2, 3, 4; there were no missing values for explanatory variables presented in Table 1.

(c) **Cohort study**—Summarise follow-up time (e.g., average and total amount)

#### Outcome data

15*

(a) **Cohort study**—Report numbers of outcome events or summary measures over time

(b) **Case-control study**—Report numbers in each exposure category, or summary measures of exposure

(c) **Cross-sectional study**—Report numbers of outcome events or summary measures

- Table 2, 3, 4, SI Table; Study population, §1, 2, 3, 4

#### Main results

16

(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included

- Table 2, 3, 4, S2 Table, S3 Table, S4 Table

(b) Report category boundaries when continuous variables were categorized

- In Methods, section Data management & Statistical analysis; Table 4, S3 Table

(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

#### Other analyses

17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity
analyses
Nutritional status of children and \textit{S. stercoralis} infection

<table>
<thead>
<tr>
<th><strong>Discussion</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key results</strong></td>
<td>18</td>
</tr>
<tr>
<td><strong>Limitations</strong></td>
<td>19</td>
</tr>
<tr>
<td><strong>Interpretation</strong></td>
<td>20</td>
</tr>
<tr>
<td><strong>Generalisability</strong></td>
<td>21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Other information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Funding</strong></td>
<td>22</td>
</tr>
</tbody>
</table>

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.*

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.